Hydrocortisone Sodium Succinate Suppliers & Bulk Manufacturers
Available Forms: Powder for reconstitution (IV/IM use)
Available Strengths: 100 mg, 250 mg, 500 mg, 1 g
Reference Brands: Solu-Cortef®(Eu & US)
Category:
Allergy Medication
Hydrocortisone Sodium Succinate is a rapid-acting corticosteroid for anaphylaxis, adrenal crisis, and acute inflammation, used IV/IM. Available in 100 mg, 250 mg, 500 mg, and 1 g vials.
Brands in US: Solu-Cortef® (Pfizer)
Brands in EU: Solu-Cortef®, Hydrocortone®, Fresenius, Teva, and generics.
Manufactured under GMP standards, ideal for hospital supply, bulk orders, and private labeling.
Hydrocortisone Sodium Succinate is available in Powder for reconstitution (IV/IM use)
and strengths such as 100 mg, 250 mg, 500 mg, 1 g.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Hydrocortisone Sodium Succinate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Hydrocortisone Sodium Succinate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Hydrocortisone Sodium Succinate Injection is a fast-acting IV/IM corticosteroid used to treat severe allergic reactions, anaphylaxis, adrenal insufficiency, and inflammatory conditions. It is widely used in emergency care across hospitals in the EU and US. The drug rapidly reduces inflammation and immune response, making it essential for acute care and critical settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing